HIV Transmission Risk: High-Risk Behaviors & Populations
HIV transmission requires sufficient viral load in body fluids (blood, semen, vaginal/rectal fluids, breast milk) and a portal of entry (mucosa, broken skin, direct bloodstream). Risk varies enormously by behavior and population.
Highest Risk Behaviors (Per-Act Probability)
- Receptive Anal Intercourse: ~1.4% (highest sexual risk) — large surface area, thin mucosa, high target cell density.
- Insertive Anal Intercourse: ~0.1%.
- Receptive Vaginal Intercourse: ~0.08%.
- Insertive Vaginal Intercourse: ~0.04%.
- Sharing Injection Equipment: ~0.6% per act (needles, syringes, cookers, cotton, water) — direct blood exposure.
- Mother-to-Child (without ART): 15–45% (pregnancy, delivery, breastfeeding). With ART (viral suppression): <1%.
Elevated Risk Populations (U.S. Epidemiology)
- Men who have sex with men (MSM): 67% of new diagnoses; biological (anal sex efficiency) + network factors.
- People who inject drugs (PWID): 7% of diagnoses; sharing equipment + sexual risk.
- Transgender women: Disproportionate burden (estimated 14% prevalence).
- Black/African American & Hispanic/Latino communities: Higher prevalence due to structural factors (access, stigma, network prevalence), not individual behavior alone.
- Sex workers & clients.
- Incarcerated populations.
- Serodiscordant couples.
- Individuals with other STIs: Ulcerative (HSV, syphilis) or inflammatory (chlamydia, gonorrhea) disrupt mucosa, ↑ target cells.
- People with TB: Immune activation, overlapping risk factors.
Lower Risk (But Not Zero)
- Oral sex (very low; case reports exist, mostly receptive fellatio with ejaculation).
- Blood transfusion/organ transplant (extremely rare with nucleic acid testing).
- Occupational needlestick (~0.3% per exposure).
Prevention Toolkit (Combination Prevention)
- Consistent condom use (external/internal).
- PrEP (Pre-Exposure Prophylaxis): TDF/FTC or TAF/FTC daily, or event-driven (2-1-1) for MSM; >99% effective when adherent. Cabotegravir LA (injectable q2mo) approved.
- PEP (Post-Exposure Prophylaxis): Start ≤72h (ideally ≤24h), 28-day course.
- Treatment as Prevention (TasP): Undetectable = Untransmittable (U=U). Viral suppression eliminates sexual transmission.
- Syringe service programs, opioid agonist therapy (methadone, buprenorphine).
- Routine opt-out screening per CDC (ages 13–64 at least once; high-risk annually).
Risk is modifiable. Tailored, combination prevention saves lives.
HIV & AIDS - Related Articles
- Internal Aids to Statutory Interpretation: A Lawyer's Toolkit
- Understanding Home HIV Tests: Accuracy & Usage
- Understanding and Combating HIV/AIDS: A Comprehensive Guide
- Understanding HIV/AIDS: Combating Stigma with Empathy and Facts
- HIV and AIDS: Causes, Types, Immune Impact, and Treatment
- Rights and Safety When Caring for HIV-Positive Nursing Home Residents
- Health Insurance for People with HIV: Options & Resources
